Nishizawa H, Pryor-Koishi K, Kato T, Kowa H, Kurahashi H, Udagawa Y
Department of Obstetrics and Gynecology, Fujita Health University, Toyoake, Japan.
Placenta. 2007 May-Jun;28(5-6):487-97. doi: 10.1016/j.placenta.2006.05.010. Epub 2006 Jul 24.
Although it has been well documented that pre-eclampsia is caused by a combination of maternal and fetal susceptibility genes, little is known about the precise etiology of this complicated disorder. To investigate how the expression of fetal genes contributes to the mechanisms underlying the progression of this disease, we have analyzed differentially expressed genes using placentas from 13 normal pregnancies and 14 pregnancies with severe pre-eclampsia. We performed genome-wide expression profiling using high-density oligonucleotide microarrays, followed by validation using real-time PCR. Among the 47,000 genes that were screened in the microarray, 137 genes were found to be differentially expressed between normal and pre-eclamptic tissues. Among these candidates, 70 were up-regulated and 67 were down-regulated. The up-regulated genes included leptin and inhibin A, which are well-known biological markers for pre-eclampsia, as well as FLT1, which was recently proved to be tightly linked with the etiology of this disease. Gene ontology analysis further revealed several biological processes that could be associated with the development of pre-eclampsia, including response to stress, host-pathogen interactions, lipid metabolism, and carbohydrate metabolism. Analyses of biological mechanisms highlighted some important pathways that may be involved in this disorder, such as the TGF-beta and CEBPA-related pathways. Furthermore, when our present subjects were classified as either severe cases of early onset or late onset pre-eclampsia, the expression of 11 genes could be correlated with the severity of this disorder. These genes may therefore prove to be novel biological markers by which the severity of this condition could be predicted. Our data are likely to be a useful future resource in the elucidation of the disease-process and in the identification of novel markers for pre-eclampsia.
尽管已有充分文献证明子痫前期是由母体和胎儿易感基因共同作用引起的,但对于这种复杂病症的确切病因仍知之甚少。为了研究胎儿基因的表达如何促成该疾病进展的潜在机制,我们使用了来自13例正常妊娠和14例重度子痫前期妊娠的胎盘,分析了差异表达基因。我们使用高密度寡核苷酸微阵列进行全基因组表达谱分析,随后通过实时PCR进行验证。在微阵列中筛选的47000个基因中,发现137个基因在正常组织和子痫前期组织之间存在差异表达。在这些候选基因中,70个上调,67个下调。上调的基因包括瘦素和抑制素A,它们是子痫前期众所周知的生物学标志物,以及FLT1,最近已证明其与该疾病的病因密切相关。基因本体分析进一步揭示了几个可能与子痫前期发展相关的生物学过程,包括应激反应、宿主-病原体相互作用、脂质代谢和碳水化合物代谢。生物学机制分析突出了一些可能参与该病症的重要途径,如TGF-β和CEBPA相关途径。此外,当我们将目前的研究对象分为早发型或晚发型子痫前期的重症病例时,11个基因的表达与该病症的严重程度相关。因此,这些基因可能被证明是预测该病症严重程度的新型生物学标志物。我们的数据可能会成为未来阐明疾病过程和识别子痫前期新型标志物的有用资源。